Efficacy of vitamin D treatment in patients diagnosed with pneumonia who require hospital admission and have vitamin D deficiency and a positive diagnosis for SARS-Cov-2 (COVID-19)

Phase 1

• Conditions: COVID-19 infection; Therapeutic area: Diseases [C] - Virus Diseases [C02]

• Registration Number: EUCTR2020-001960-28-ES
• Lead Sponsor: Investigation Institute Bioaraba

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-26
• Last Update Posted: 30 November 2020

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

- Older patients of both sexes
- Admitted to the Respiratory and / or Internal Medicine Unit of the Hospital De Santiago, the OSI Araba HUA is walking due to pneumonia
- Possibility for observation during the treatment period
- Signature of written and, exceptionally oral, informed consent
- Have requested the test for SARS-CoV-2 (nasopharyngeal exudate PCR) and obtain positive results
- Having a deficiency of vitamin D (25 (OH) vitamin D), defined by blood levels below 30 mg / ml
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 70
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 48

Exclusion Criteria

- Patients taking any type of vitamin D supplement
- Patients with hypoparathyroidism
- Pregnant or lactating women
- Patients in whom vitamin D administration is formally contraindicated
- Patients who cannot take vitamin D orally at the time of enrollment

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified